Skip to main navigation Skip to search Skip to main content

Clinical outcomes of ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Korean multicenter, retrospective analysis

Research output: Contribution to journal › Journal article › peer-review

Original languageKorean
JournalAnnals of Oncology
StatePublished - 2019.11.1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this